Favicon
Favicon

New Research from the Ragon and Broad Unveils the Protective Role of CD4+ T Cells in Tuberculosis Reinfection

Date: September 24, 2024 By: Nick Kolev

Researchers from the Shalek Lab at the Ragon Institute of Mass General Brigham, MIT, and Harvard, in collaboration with the Broad Institute, have uncovered key insights into how prior Mycobacterium tuberculosis (Mtb) infection primes the immune system for enhanced protection against reinfection. This study, published in Immunity on August 30, used a non-human primate model to demonstrate that previous Mtb infection leads to a durable, protective immune response that is dependent on CD4+ T cells.

The research examined the lungs after an initial Mtb infection and found that having CD4+ T cells present during a second infection makes the lung environment less inflamed. The study showed that CD4+ T cells help change the behavior of CD8+ T cells, reduce the number of certain immune cells called neutrophils, and lower specific immune signals in other cells, indicating a shift toward a more regulated immune response.

These findings open new avenues for developing vaccines and therapeutics that not only target lymphocytes but also modulate innate immune cells, offering promising strategies to limit tuberculosis disease and improve patient outcomes.

More News

Press Releases

Ringel Lab Study Reveals Age-Related Decline in Tumor-Fighting T Cells and Its Impact on Cancer Treatment

Researchers at the Ragon Institute of Mass General Brigham, MIT, and Harvard have uncovered critical insights into how aging impairs the immune system’s ability to fight cancer.

Press Releases

New Research from the Ragon and Broad Unveils the Protective Role of CD4+ T Cells in Tuberculosis Reinfection

This study, published in Immunity on August 30, used a non-human primate model to demonstrate that previous Mtb infection leads to a durable, protective immune response that is dependent on CD4+ T cells.

Press Releases

MIT News – A two-dose schedule could make HIV vaccines more effective

MIT researchers find that the first dose primes the immune system, helping it to generate a strong response to the second dose, a week later.